A detailed history of Baker Avenue Asset Management, LP transactions in Biogen Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 1,241 shares of BIIB stock, worth $184,933. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,241
Holding current value
$184,933
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$189.07 - $236.8 $234,635 - $293,868
1,241 New
1,241 $240,000
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $31,662 - $35,736
125 Added 215.52%
183 $47,000
Q2 2023

Aug 11, 2023

SELL
$275.25 - $318.06 $275 - $318
-1 Reduced 1.69%
58 $16,000
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $256 - $292
1 Added 1.72%
59 $16,000
Q4 2022

Feb 13, 2023

BUY
$252.44 - $306.72 $14,641 - $17,789
58 New
58 $16,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Baker Avenue Asset Management, LP Portfolio

Follow Baker Avenue Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Avenue Asset Management, LP with notifications on news.